Current state of theranostics in metastatic castrate-resistant prostate cancer

被引：2

作者：

Nindra, Udit ^{[1
,2
,3
,6
]}

Lin, Peter ^{[2
,3
,4
]}

Becker, Therese ^{[2
,3
,5
]}

Roberts, Tara L. ^{[2
,3
,5
]}

Chua, Wei ^{[1
,2
,3
]}

机构：

[1] Liverpool Hosp, Dept Med Oncol, Sydney, NSW, Australia

[2] Ingham Inst Appl Med Res, Sydney, NSW, Australia

[3] Western Sydney Univ, Sydney, NSW, Australia

[4] Liverpool Hosp, Dept Nucl Med, Sydney, NSW, Australia

[5] Univ New South Wales, Sydney, NSW, Australia

[6] Liverpool Hosp, Dept Med Oncol, Liverpool, NSW 2170, Australia

来源：

JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY | 2024年 / 68卷 / 04期

关键词：

Lutetium PSMA; prostate cancer; radiopharmaceutical; theranostics; PAINFUL BONE METASTASES; CLINICAL-EXPERIENCE; DOUBLE-BLIND; SR-89; THERAPY; MULTICENTER; RADIUM-223; EFFICACY; CHLORIDE; AC-225-PSMA-617;

D O I：

10.1111/1754-9485.13658

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Prostate cancer remains one of the leading causes of cancer-related death in the world. There have been significant advances in chemotherapy, hormonal therapy and targeted therapy options for patients with castrate-resistant disease. However, these systemic treatments are often associated with unwanted toxicities. Targeted therapy with radiopharmaceuticals has become of key interest to limit systemic toxicity and provides a more precision oncology approach to treatment. Strontium-89, Samarium-153 EDTMP and Radium-223 have been trialled with mixed results. Strontium-89 and Samarium-153 EDTMP have shown benefits in palliating metastatic bone pain but with no impact on survival outcomes. Early therapeutic radiopharmaceuticals targeting PSMA that were developed were beta-emitting agents, but recently alpha-emitting agents are being investigated as potentially superior options. Radium-223 is the first alpha-particle emitter therapeutic agent approved by the FDA, with phase III trial evidence showing benefits in overall survival and delay in symptomatic skeletal events for patients. Recently, 177-Lutetium-PSMA-617 has demonstrated significant survival advantages in pre-treated metastatic castrate-resistant cancer patients in a number of phase II and III studies. Furthermore, 225-Actinium-PSMA-617 also showed promise even in patients pre-treated with 177-Lutetium-PSMA-617. Hence, there has been an explosion of radiopharmaceutical treatment options for patients with prostate cancer. This review explores past and current theranostic capacities in the radiopharmaceutical treatment of metastatic castrate-resistant prostate cancer.

引用

页码：412 / 420

页数：9

共 34 条

[1] Immunogenic priming with 177Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study. [J].

Aggarwal, Rahul Raj ;

Sam, Srey Luch ;

Koshkin, Vadim S. ;

Small, Eric Jay ;

Feng, Felix Y. ;

de Kouchkovsky, Ivan ;

Kwon, Daniel H. ;

Friedlander, Terence W. ;

Borno, Hala ;

Bose, Rohit ;

Chou, Jonathan ;

Desai, Arpita ;

Rodvelt, Tammy J. ;

Aslam, Maya ;

Rastogi, Medini ;

Fong, Lawrence ;

Hope, Thomas A. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[2] Repetitively dosed docetaxel and 153Samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer [J].

Autio, Karen A. ;

Pandit-Taskar, Neeta ;

Carrasquillo, Jorge A. ;

Stephenson, Ryan D. ;

Slovin, Susan F. ;

Rathkopf, Dana E. ;

Hong, Christina ;

Heller, Glenn ;

Scher, Howard I. ;

Larson, Steven M. ;

Morris, Michael J. .

CANCER, 2013, 119 (17) :3186-3194

[3]

Bal C, 2019, J NUCL MED, V60

[4]

BLAKE GM, 1988, J NUCL MED, V29, P549

[5] 153Sm-EDTMP for Pain Relief of Bone Metastases from Prostate and Breast Cancer and Other Malignancies [J].

Correa-Gonzalez, Luis ;

Arteaga de Murphy, Consuelo ;

Pichardo-Romero, Pablo ;

Pedraza-Lopez, Martha ;

Moreno-Garcia, Claudia ;

Correa-Hernandez, Luis .

ARCHIVES OF MEDICAL RESEARCH, 2014, 45 (04) :301-308

[6] Prospective evaluation of samarium-153-EDTMP radionuclide treatment for bone metastases in patients with hormone-refractory prostate cancer [J].

Dolezal, J. ;

Vizda, J. ;

Odrazka, K. .

UROLOGIA INTERNATIONALIS, 2007, 78 (01) :50-57

[7]

Feuerecker B., 2019, J Med Imaging Radiat Sci, V50, pS20, DOI 10.1016/j.jmir.2019.03.066

[8] Palliative effects and adverse events of strontium-89 for prostate cancer patients with bone metastasis [J].

Furubayashi, Nobuki ;

Negisiii, Takahito ;

Ura, Shintaro ;

Hirai, Yoshiki ;

Nakamura, Motonobu .

MOLECULAR AND CLINICAL ONCOLOGY, 2015, 3 (01) :257-263

[9] Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study [J].

Gafita, Andrei ;

Calais, Jeremie ;

Grogan, Tristan R. ;

Hadaschik, Boris ;

Wang, Hui ;

Weber, Manuel ;

Sandhu, Shahneen ;

Kratochwil, Clemens ;

Esfandiari, Rouzbeh ;

Tauber, Robert ;

Zeldin, Anna ;

Rathke, Hendrik ;

Armstrong, Wesley R. ;

Robertson, Andrew ;

Thin, Pan ;

D'Alessandria, Calogero ;

Rettig, Matthew B. ;

Delpassand, Ebrahim S. ;

Haberkorn, Uwe ;

Elashoff, David ;

Herrmann, Ken ;

Czernin, Johannes ;

Hofman, Michael S. ;

Fendler, Wolfgang P. ;

Eiber, Matthias .

LANCET ONCOLOGY, 2021, 22 (08) :1115-1125

[10] Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis. [J].

Gillessen, Silke ;

Choudhury, Ananya ;

Rodriguez-Vida, Alejo ;

Nole, Franco ;

Diaz, Enrique Gallardo ;

Roumeguere, Thierry Andre ;

Daugaard, Gedske ;

Loriot, Yohann ;

Saad, Fred ;

McDermott, Raymond S. ;

Neven, Anouk ;

Fournier, Beatrice ;

Tombal, Bertrand F. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 →